Novartis Financial Results – Q1 2022
Novartis announced the company’s financial results for the first quarter of 2022.
New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
Novartis resumes production and delivery of radioligand therapy medicines ahead of schedule
New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.
Novartis in Society Integrated Report 2021
In 2021, we continued to reimagine medicine and deliver on our purpose to improve and extend people’s lives. See more in our Integrated Report.
Environmental, Social and Governance
Novartis aims to hold itself to the highest standards of sustainability and ethical business practices.
Novartis COVID-19 Information Center
Novartis is responding to the coronavirus disease (COVID-19) outbreak. The information center provides a central hub for news, guidance and resources.
Live is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company.
Novartis Gene Therapies Global Managed Access Program
Novartis Gene Therapies recommits to Global Managed Access Program for 2021 so that children around the world can benefit from SMA treatment who otherwise would not have access to Zolgensma.